<DOC>
	<DOC>NCT02516085</DOC>
	<brief_summary>The purpose of the study is to show that the intake of L-arginine and metformin improves muscle function and delays disease progression in patients with Duchenne's muscular dystrophy.</brief_summary>
	<brief_title>Improved Muscle Function in Duchenne Muscular Dystrophy Through L-Arginine and Metformin</brief_title>
	<detailed_description>This is an investigator-initiated, open-label, single-center, proof-of-concept-study. The study medication consists of L-arginine and metformin. The duration of the study is 16 weeks and comprehends one screening and four study visits.</detailed_description>
	<mesh_term>Muscular Dystrophies</mesh_term>
	<mesh_term>Muscular Dystrophy, Duchenne</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Molecular diagnosis of DMD Patients 7 10 years of age at time of screening Ambulant Previous (3 months or less) or concomitant participation in another therapeutic trial Use of Larginine, Lcitrulline or metformin within the last 3 months Known individual hypersensitivity to Lcitrulline or metformin Other chronic disease or clinical relevant limitation of renal, liver, heart function according to discretion of the investigator</criteria>
	<gender>All</gender>
	<minimum_age>7 Years</minimum_age>
	<maximum_age>10 Years</maximum_age>
	<verification_date>August 2015</verification_date>
</DOC>